By A high-stakes showdown is erupting in the nation’s health establishment as Robert F. Kennedy Jr., newly installed as Secretary of Health and Human Services, confronts a $2 million campaign by the pharmaceutical lobby to drive him from office. The plan, disclosed in a leaked memo from the Biotechnology Innovation Organization (BIO), highlights the escalating conflict between Kennedy’s “Make America Healthy Again” agenda and the industry’s entrenched interests.
The memo, first obtained by the Brownstone Institute in July, lays out BIO’s blueprint to pressure lawmakers and opinion leaders into demanding Kennedy’s resignation, writes The National File. Representing giants like Pfizer, Moderna, Merck, Eli Lilly, and Johnson & Johnson, BIO warned members that Kennedy’s leadership threatened predictable vaccine approval pathways. The strategy aimed for a September push—timed to coincide with Kennedy’s scheduled Senate testimony this week.
In July, the Brownstone Institute EXPOSED a leaked memo from BIO, the lobbying arm for Pfizer, Moderna, Merck, Eli Lilly, and Johnson & Johnson.
The memo made their goal clear:
“It’s time to go to The Hill and lobby that it is time for RFK Jr. to go.”
Why?
Because RFK Jr. and… pic.twitter.com/HzbDV9Gf5b
— Holden Culotta (@Holden_Culotta) September 2, 2025
Kennedy has already rattled the public health bureaucracy. His abrupt dismissal of CDC Director Susan Monarez last week threw the agency into turmoil, prompting a wave of high-profile resignations. Among them was Dr. Demetre Daskalakis, a Biden ‘satanist’ in charge of children’s health, who blasted Kennedy’s “anti-science” stance in his resignation letter. Nine former CDC directors added fuel to the fire, publishing a joint article condemning Kennedy’s policies as a danger to public health.
The uproar comes as Kennedy presses forward with reforms designed to upend business as usual. He has slashed $500 million earmarked for mRNA vaccine development and restructured the Advisory Committee on Immunization Practices to emphasize independence from pharmaceutical ties. These moves, part of his broader MAHA platform, also target chronic disease, food additives, and water fluoridation—areas Kennedy argues have been neglected under industry-driven policy.
The backlash has spilled into Congress. Senator Bernie Sanders, who received millions from what he has previously derided as “Big Pharma,” is leading calls for Kennedy’s resignation, echoing warnings from the American Academy of Pediatrics and the American Medical Association. However, Kennedy’s allies point out that both groups receive substantial funding from the heavy industry sector, raising concerns about their impartiality.
Meanwhile, reports suggest the CDC itself has circulated internal memos on how to obstruct Kennedy’s reforms. That resistance builds on longstanding controversies, from the agency’s eugenics-era policies to recent disputes over vaccine safety data—issues Kennedy has vowed to revisit.
As Kennedy prepares for his Senate testimony, the battle lines are stark. His reforms threaten to recast the balance of power in public health. Still, the pharmaceutical industry’s coordinated push to oust him signals a fight that could shape the trajectory of health policy under the Trump administration.
What will emerge goes beyond just personnel disputes It is a struggle over who controls the future of American health. The outcome will determine whether Kennedy’s reforms take hold or whether the industry succeeds in preserving the status quo.
[Read More: Pro-Terror ‘People’s Conference’ Heads To Detroit]
